• 1. Retracted Article: Metabolomics reveals that PPARα activation protects against lithocholic acid-induced liver injury
  Qi Zhao,Rui Yang,Fang Liu,Jing Wang,Dan-Dan Hu,Xiu-Wei Yang,Fei Li RSC Adv. 2017 7 49849
• 2. Caffeic acid supplementation ameliorates intestinal injury by modulating intestinal microbiota in LPS-challenged piglets
  Xiaobin Wen,Fan Wan,You Wu,Lei Liu,Yueping Liu,Ruqing Zhong,Liang Chen,Hongfu Zhang Food Funct. 2023 14 7705
• 3. Apple polyphenol extract modulates bile acid metabolism and gut microbiota by regulating the circadian rhythms in daytime-restricted high fat diet feeding C57BL/6 male mice
  Yuan Cui,Yan Yin,Shilan Li,Zhengli Wu,Yisha Xie,Qingfan Qian,Hao Yang,Xinli Li Food Funct. 2022 13 2805
• 4. Targeting gut microbial bile salt hydrolase (BSH) by diet supplements: new insights into dietary modulation of human health
  Yanan Yang,Chongming Wu Food Funct. 2022 13 7409
• 5. Polysaccharides from Enteromorpha prolifera alleviate hypercholesterolemia via modulating the gut microbiota and bile acid metabolism
  Changwei Yang,Shiying Huang,Zaigang Lin,Hui Chen,Caihong Xu,Yiqi Lin,Huiyu Sun,Fang Huang,Dai Lin,Fuchuan Guo Food Funct. 2022 13 12194

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Taurinated bile acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Bile acids, alcohols and derivatives Taurinated bile acids and derivatives

Taurohyodeoxycholic Acid Sodium Salt: A Comprehensive Overview

Taurohyodeoxycholic acid sodium salt, with the CAS number 2958-04-5, is a bile acid derivative that has garnered significant attention in the fields of pharmacology and medical research. This compound is a sodium salt of taurohyodeoxycholic acid, which is a naturally occurring bile acid found in the human body. The compound is widely studied for its potential therapeutic applications, particularly in the treatment of liver diseases, metabolic disorders, and certain types of cancer.

Taurohyodeoxycholic acid sodium salt has been extensively researched for its role in modulating bile acid metabolism. Recent studies have highlighted its ability to regulate cholesterol homeostasis and improve liver function. The compound is known to activate the farnesoid X receptor (FXR), a nuclear receptor that plays a critical role in bile acid synthesis and lipid metabolism. This property makes it a promising candidate for the development of drugs targeting metabolic syndrome and non-alcoholic fatty liver disease (NAFLD).

The chemical structure of taurohyodeoxycholic acid sodium salt consists of a cholestane skeleton with hydroxyl and sulfonic acid groups. The sulfonation process enhances its solubility and bioavailability, making it suitable for systemic administration. Researchers have also explored its anti-inflammatory and antioxidant properties, which are attributed to its ability to reduce reactive oxygen species (ROS) and inhibit pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).

One of the most exciting developments in recent years is the investigation of taurohyodeoxycholic acid sodium salt as a potential anticancer agent. Preclinical studies have demonstrated its ability to induce apoptosis in various cancer cell lines, including those derived from hepatocellular carcinoma, breast cancer, and colorectal cancer. The compound's mechanism of action involves the modulation of key signaling pathways such as the PI3K/AKT/mTOR pathway, which is often dysregulated in cancer cells.

In addition to its therapeutic potential, taurohyodeoxycholic acid sodium salt has been studied for its role in gut microbiota modulation. Emerging evidence suggests that bile acids play a crucial role in maintaining gut health by influencing the composition and activity of the microbiome. The compound's ability to regulate gut microbiota could have implications for the treatment of inflammatory bowel disease (IBD) and other gastrointestinal disorders.

The synthesis and characterization of taurohyodeoxycholic acid sodium salt have also been optimized in recent years. Researchers have developed efficient methods for large-scale production, ensuring that the compound is available for preclinical and clinical studies. Advanced analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry have been employed to ensure the purity and stability of the compound.

Despite its promising properties, further research is needed to fully understand the safety profile and efficacy of taurohyodeoxycholic acid sodium salt in humans. Ongoing clinical trials are evaluating its tolerability and pharmacokinetics in healthy volunteers and patients with liver diseases. These studies are expected to provide critical insights into its potential as a therapeutic agent.

In conclusion, taurohyodeoxycholic acid sodium salt represents a novel class of bile acid derivatives with diverse therapeutic applications. Its ability to modulate bile acid metabolism, regulate inflammation, and influence cancer cell signaling makes it a compelling candidate for drug development. As research continues to uncover its mechanisms of action and clinical potential, this compound holds great promise for advancing medical treatments in various disease areas.

• 32747-06-1(Taurocholat)
• 516-50-7(Taurodeoxycholic acid)
• 107656-89-3(Taurocholat)
• 90082-01-2(Taurocholat)
• 81-24-3(TAUROCHOLIC ACID)
• 124612-77-7(Ethanesulfonic acid,2-[[(3a,5b,6b)-3,6-dihydroxy-24-oxocholan-24-yl]amino]- (9CI))
• 5571-91-5(Ethanesulfonic acid,2-[[(5b,7a,12a)-7,12-dihydroxy-24-oxocholan-24-yl]amino]- (9CI))
• 59005-70-8(Ethanesulfonic acid,2-[[(3a,5a,7a,12a)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-)
• 252030-90-3(Taurocholic Acid-d4)
• 86386-60-9(Tauroursocholic acid)